Weight loss jabs could almost halve risk of obesity-related cancers beyond slimming down, study suggests
- Researchers examined health records of 6,356 obese adults with type 2 diabetes who received either GLP-1 receptor agonist treatments or underwent bariatric surgery during the period from 2010 to 2018 in Israel.
- The study compared these patients, matched by age, sex, BMI, smoking status, and treatment time, to assess obesity-related cancer risk over about 7.5 years.
- Results showed similar rates of obesity-related cancers, predominantly postmenopausal breast, colorectal, and uterine cancers, occurred in both treatment groups despite greater weight loss in surgery patients.
- GLP-1 receptor agonists reduced obesity-related cancer risk by 41% beyond weight loss effects, possibly through mechanisms like inflammation reduction, according to co-lead authors Dr Yael Wolff Sagy and Professor Dror Dicker.
- As an observational study, these findings need confirmation in large randomized trials, with future research also required to evaluate effects of newer GLP-1 drugs and non-obesity-related cancer risks.
46 Articles
46 Articles
Why it's getting easier to get a weight-loss jab on the NHS
Some NHS patients are now getting weight-loss jabs through apps that can replace face-to-face visits with doctors.It comes as the first study results show that treatment via smartphone gives similar weight loss as when people have regular hospital appointments.People getting Wegovy (or Ozempic when used for diabetes – both of which come from the drug semaglutide) through one such app lost 17 per cent of their weight after a year.And a separate a…
Weight-Loss Drugs Like Ozempic May Slash Cancer Risk By 50%, Landmark Israeli Study Finds
A groundbreaking Israeli study has found that GLP-1 medications — the popular class of weight-loss drugs that includes Ozempic and Wegovy — can dramatically reduce the risk of developing obesity-related cancers, surpassing even the benefits of bariatric surgery. The findings, published in The Lancet’s eClinicalMedicine, analyzed thousands of patients with obesity and type 2 diabetes who were prescribed GLP-1 drugs such as liraglutide (Saxenda), …
Weight-Loss Drugs Could Slash Cancer Risk by 41%—Here’s Who Benefits
The negative side effects of weight-loss injections tend to get all the attention. After all, who's going to scroll by a headline about "floppy feet" or an "extremely serious" stomach condition? But for every scary story, there's probably another that touts the benefits—both intended and not—of popular medications like Wegovy, Ozempic, and Zepbound. And could anything be better news than the fact that these drugs could potentially cut some patie…
Study Suggests Weight Loss Drugs Can Reduce Cancer Risk
The fact that there is a connection between obesity and an increased risk of cancer is not news at this point, but the specifics of that connection are still being charted. As the National Cancer Institute pointed out on its website, “there is consistent evidence that higher amounts of body fat are associated with an increased risk of a number of cancers.” A 2023 study found that a person’s weight can put them a higher risk for more types of can…
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage